Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
The Mechanism of Action of CDK4/6 Inhibitors
Related Items


TON Web Exclusives published on February 26, 2018 in Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Last modified: January 10, 2018